Beone Medicines Ltd.
An oncology-focused biopharmaceutical company that develops and sells medicines for blood cancers, including Brukinsa, used to treat leukemia and lymphoma. Founded in Beijing in 2010 by John Oyler and Xiaodong Wang, it was originally called BeiGene — a blend of "Beijing" and "gene" — before rebranding as BeOne in 2024, a name chosen to reflect its mission against cancer: "Be" stands for patients' goal to be free of disease, and "One" for uniting people in that fight.
American Depositary Receipt (each representing 13 ordinary shares)
Sold 22.00M
Granted 10.70M · Sold 1.35M
Bought 165.5K
Granted 875.7K · Sold 458.5K
Granted 265.7K · Sold 2.88M
Granted 2.53M · Sold 37.0K
Granted 46.0K
Granted 1.48M · Sold 326.6K
Granted 410.1K · Sold 5.0K
Granted 422.8K · Sold 46.3K
Granted 41.7K · Sold 25.5K
Granted 85.2K · Sold 698
Granted 75.9K
Granted 75.9K · Sold 212
Granted 75.9K · Sold 212
Granted 62.2K · Sold 6.1K
Granted 46.3K
Granted 29.6K
Granted 56.9K · Sold 235
Granted 19.0K
Granted 19.0K
Granted 38.1K
Granted 421.6K · Sold 1.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| HHLR Advisors, LTD. +1 co-filer10% owner · 10 transactions | — | 125.05Mas of Dec 2024 | — | — | 22.00M |
| Oyler JohnChief Executive Officer, Director · 262 transactions | — | 95.85M | 10.70M | — | 1.35M |
| Amgen Inc10% owner · 1 transaction | +0.9% | 18.94Mas of Sep 2021 | — | 165.5K | — |
| Wang XiaodongDirector, Chair, Scientific Advisory Brd · 174 transactions | +30% | 14.82M | 875.7K | — | 458.5K |
| Baker Bros. Advisors LP +5 co-filersDirector · 22 transactions | — | 8.54M | 265.7K | — | 2.88M |
| Wang LaiPresident, Global Head of R&D · 58 transactions | — | 2.88M | 2.53M | — | 37.0K |
| Glazer Donald W.Director · 4 transactions | -1.3% | 2.72Mas of Jun 2024 | 46.0K | — | — |
| Wu XiaobinPresident and COO · 132 transactions | +17.5% | 1.29M | 1.48M | — | 326.6K |
| Wang Julia AijunChief Financial Officer · 17 transactions | +408.6% | 426.6Kas of Jul 2024 | 410.1K | — | 5.0K |
| Lee Chan HenrySVP, General Counsel · 79 transactions | — | 338.9K | 422.8K | — | 46.3K |
| Huang JaneCMO, Hematology · 58 transactions | -46.4% | 160.1Kas of Dec 2021 | 41.7K | — | 25.5K |
| Ball Titus B.Principal Accounting Officer · 10 transactions | — | 99.6K | 85.2K | — | 698 |
| Hooper Anthony CDirector · 5 transactions | +973.3% | 83.7K | 75.9K | — | — |
| Dugan MargaretDirector · 6 transactions | — | 73.2K | 75.9K | — | 212 |
| Riva AlessandroDirector · 6 transactions | — | 73.2K | 75.9K | — | 212 |
| Sanders Corazon (Corsee) D.Director · 12 transactions | +598.3% | 54.5K | 62.2K | — | 6.1K |
| Brandicourt OlivierDirector · 3 transactions | — | 46.3K | 46.3K | — | — |
| Malley ThomasDirector · 2 transactions | 0% | 30.0Kas of Jun 2023 | 29.6K | — | — |
| Yi QingqingDirector · 7 transactions | +211.2% | 24.3K | 56.9K | — | 235 |
| Mooney Elizabeth FisherDirector · 1 transaction | — | 19.0K | 19.0K | — | — |
| Sawyers Charles LazelleDirector · 1 transaction | — | 1.9K | 19.0K | — | — |
| Sharp ShaliniDirector · 3 transactions | — | 9 | 38.1K | — | — |
| Rosenberg AaronChief Financial Officer · 8 transactions | — | 0 | 421.6K | — | 1.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -26.98M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.